Literature DB >> 16265127

Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease.

Jon O Lundberg1, Per M Hellström, Magne K Fagerhol, Eddie Weitzberg, Arne G Roseth.   

Abstract

Distinguishing patients with inflammatory bowel disease from those with irritable bowel syndrome can be difficult. A simple and reliable test that detects intestinal inflammation would therefore be very useful in the clinic. If such a test parameter correlated with the intensity of the inflammatory reaction it could also be used to monitor disease activity. Calprotectin, lactoferrin and nitric oxide are produced and released locally in much greater quantities in the inflamed gut than in the noninflamed gut. These compounds can be readily measured in fecal samples (calprotectin and lactoferrin) or directly in the intestinal lumen (nitric oxide gas). Here, we discuss what is known about these markers, how they could be used in clinical practice and how they can complement existing techniques used for the diagnosis and monitoring of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16265127     DOI: 10.1038/ncpgasthep0094

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  20 in total

1.  Non-invasive markers of gut wall integrity in health and disease.

Authors:  Joep P M Derikx; Misha D P Luyer; Erik Heineman; Wim A Buurman
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

2.  Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders.

Authors:  Tryggve Ljung; Sofie Lundberg; Mark Varsanyi; Catharina Johansson; Peter T Schmidt; Max Herulf; Jon O Lundberg; Per M Hellstrom
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

3.  Inflammatory biomarkers predict relapse in IBD.

Authors:  P Hanaway; A Roseth
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

4.  Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury.

Authors:  Frank Heller; Sandra Frischmann; Maria Grünbaum; Walter Zidek; Timm H Westhoff
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 8.237

Review 5.  Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update.

Authors:  Cansel Turkay; Benan Kasapoglu
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

6.  The Place of Calprotectin, Lactoferrin, and High-Mobility Group Box 1 Protein on Diagnosis of Acute Appendicitis with Children.

Authors:  Sevgi Buyukbese Sarsu; Ayse Binnur Erbagci; Hasan Ulusal; Suleyman Cuneyt Karakus; Özlem Gümüstekin Bulbul
Journal:  Indian J Surg       Date:  2016-01-14       Impact factor: 0.656

7.  Increased prevalence of gastrointestinal viruses and diminished secretory immunoglobulin a levels in antibody deficiencies.

Authors:  A A J M van de Ven; W J M Janssen; L S Schulz; A M van Loon; K Voorkamp; E A M Sanders; J G Kusters; S Nierkens; M Boes; A M J Wensing; J M van Montfrans
Journal:  J Clin Immunol       Date:  2014-08-19       Impact factor: 8.317

Review 8.  The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.

Authors:  James D Lewis
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

Review 9.  Epithelial Barrier Function in Gut-Bone Signaling.

Authors:  Naiomy Deliz Rios-Arce; Fraser L Collins; Jonathan D Schepper; Michael D Steury; Sandi Raehtz; Heather Mallin; Danny T Schoenherr; Narayanan Parameswaran; Laura R McCabe
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

10.  Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.

Authors:  Taojun He; Samuel E Kaplan; Luz A Gomez; Xuedong Lu; Lakshmi V Ramanathan; Mini Kamboj; Yi-Wei Tang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-21       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.